Shawn D. Hingtgen, Ph.D.

Pairing a newly developed gel with immunotherapy that was delivered to post-surgical mouse brains with glioblastoma, a highly malignant and deadly cancer, improved the immunotherapy’s effectiveness, report researchers from the University of North Carolina Lineberger Comprehensive Cancer Center and colleagues. The findings appeared on Oct. 6, 2021, in Science Advances.

The researchers used CAR-T cell (chimeric antigen receptor-T cell) immunotherapy, which involves harvesting immune-system T cells from a patient and genetically re-engineering them in the lab to recognize targets on the surface of cancer cells. In this mouse study, the CAR-T cells and gel were placed to fill in the area where a glioblastoma tumor had just been surgically removed. Previous studies have shown that administering T cells alone have produced limited benefit… Continue reading.

WASHINGTON, D.C. — The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of Shawn D. Hingtgen, Ph.D., to its College of Fellows. Dr. Hingtgen was nominated, reviewed, and elected by peers and members of the College of Fellows for pioneering work on application of novel nanomaterial-cell composite therapy for post-surgical brain cancer.

The College of Fellows is comprised of the top two percent of medical and biological engineers in the country. The most accomplished and distinguished engineering and medical school chairs, research directors, professors, innovators, and successful entrepreneurs comprise the College of Fellows. AIMBE Fellows are regularly recognized for their contributions in teaching, research, and innovation. AIMBE Fellows have been awarded the Nobel Prize, the Presidential Medal of Science and the Presidential Medal of Technology and Innovation and many also are members of the National Academy of Engineering, National Academy of Medicine, and the National Academy of Sciences… Continue reading.